Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Macrosteatotic Liver Transplantation
NCT03468140Phase 1Withdrawn
- Sponsor
- Yale University
- Start
- Oct 2021
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of eculizumab in liver disease (2 arms), sponsored by Yale University. Primary endpoint: Degree of Hepatocellular Injury. Planned start Oct 2021; status: withdrawn.
02
Drugs
eculizumab
03
Conditions
liver disease
Beyond the preview
Go deeper on NCT03468140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468140.